PART随机试验方案:前列腺癌局部消融对比根治性治疗
PART是一项英国多中心、实用性随机对照试验,旨在评估局部消融(PA,包括HIFU或IRE)对比根治性治疗(RT,包括根治性前列腺切除术、根治性放疗或LDR近距离放疗)在局限期中危前列腺癌(irPCa)中的肿瘤学治疗成功是否非劣效。基于RT和PA的肿瘤学治疗成功分别为95%和85%、非劣效界值20%、中位随访3年,需招募275名男性(每组137名,1:1随机),把握度80%,单侧α=0.025;考虑10%退出或脱落率,需招募并随机306名参与者。
要点
- PA对比RT在局限期中危前列腺癌中肿瘤学治疗成功的非劣效性。
- 样本量基于RT 95%和PA 85%成功率、20%非劣效界值计算。
- 需招募306名参与者以允许10%退出或脱落率。
核心结论
- PART试验将提供稳健的前瞻性数据和高级别随机证据,以确定PA对比RT在局限期中危前列腺癌中的肿瘤学治疗有效性。
研究设计与样本
- 英国全国、多中心、实用性、随机对照试验(ISRCTN17249875),比较PA(HIFU或IRE)与RT(根治性前列腺切除术、根治性放疗或LDR-B)。
- 基于RT和PA的肿瘤学治疗成功分别为95%和85%、非劣效界值20%、中位随访3年,需招募275名男性(每组137名,1:1随机),把握度80%,单侧α=0.025;允许10%退出或脱落率后需306名参与者。
关键数值与推荐
- 主要结局:PA的治疗成功通过前列腺活检和影像学确定,RT使用标准定义。
- PA采用HIFU或IRE取决于病灶位置;RT采用根治性前列腺切除术、根治性放疗或LDR-B取决于患者和医生偏好。
临床怎么用
- 试验结果将用于告知局限期中危前列腺癌的临床决策,包括肿瘤学疗效、副作用、健康相关生活质量和成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary objective: to determine whether prostate gland partial ablation (PA) has non-inferior oncological treatment success vs radical treatment (RT) of localised intermediate-risk prostate cancer (irPCa). SECONDARY OBJECTIVES: to compare (i) participant-reported urinary and sexual dysfunction side effects, (ii) short/medium term serious adverse events, (iii) health-related quality of life (HRQoL), (iv) cost-effectiveness; and to report (v) the need for repeat PA, (vi) accuracy of magnetic resonance imaging and biopsy protocols in determining suitability for PA, (vii) disease progression, local spread and metastases, (viii) medium-term disease-specific and overall mortality. PARTICIPANTS AND METHODS: The 'Partial prostate Ablation versus Radical Treatment' (PART; International Standard Randomised Controlled Trial Number ISRCTN17249875) is a UK-wide, multicentre, pragmatic, randomised controlled trial investigating whether PA (high-intensity focused ultrasound [HIFU] or irreversible electroporation [IRE]) is non-inferior to RT (radical prostatectomy, radical radiotherapy, or low-dose-rate brachytherapy [LDR-B]) in treating localised irPCa. A Qualitative Research Integrated within Trials (QuinteT) Recruitment Intervention is included to optimise recruitment and informed consent. Primary outcome treatment success for PA will be determined by prostate biopsies and imaging, and for RT using standard definitions. Participants will receive treatment according to their randomised allocation, with HIFU or IRE for PA depending on lesion location, and radical prostatectomy, radical radiotherapy, or LDR-B according to patient and physician preference for RT. Based on 95% and 85% oncological treatment success for RT and PA, respectively, with a non-inferiority margin of 20%, at median 3 years of follow-up, PART requires 275 recruited men (137 per group, randomised on a 1:1 basis), for 80% power, with a one-sided alpha of 0.025. Allowing for a 10% total withdrawal or dropout rate, PART requires 306 recruited and randomised participants. CONCLUSIONS: The PART trial will provide robust prospective data and high-level randomised evidence to determine oncological treatment effectiveness of PA vs RT for localised irPCa, along with comparative side effect, HRQoL, and health economics evaluations, to inform clinical decision-making.
引用
- Bryant RJ, Leslie T, Laniado M, et al. The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. BJU Int. 2026. PMID: 42760023. doi:10.1111/bju.70448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。